Wegovy 2.5mg for weight loss: what to expect from the first pen

Your first pen has arrived, and it feels underwhelming

Picture the scene: you've done your research, you know semaglutide can produce meaningful weight loss, and the pen you're injecting each week is set to the lowest possible dose. It's natural to feel impatient, or to wonder whether something has gone wrong. Nothing has. The 2.5mg starting phase is written into Wegovy's licensed dosing schedule for a clear reason: semaglutide slows gastric emptying and acts on appetite centres in the brain, and introducing it gradually gives your digestive system time to settle. Jump straight to a higher dose and the nausea, bloating and indigestion that can accompany early treatment tend to be significantly worse. The slow start is the shortcut, in a sense.

During these first four weeks, most people notice relatively little change in appetite or the number on the scales, and that is entirely expected. Clinically, this phase is about safety and tolerability, not weight reduction. One practical habit worth building now: check the injection site you've used each week and rotate it (abdomen, thigh, upper arm) so no single area becomes irritated. It takes under a minute and makes a real difference to comfort over the months ahead. The full Wegovy dosing schedule explains how each stage builds on the last.

When does the dose that actually shifts weight kick in?

Wegovy's titration pathway moves in roughly four-week steps: after the 2.5mg opener, doses escalate through 0.5mg, 1mg, 1.7mg and finally 2.4mg. Each increase is subject to your prescriber's review, there's no automatic progression. If a particular step causes persistent side effects, staying at that level for a further four weeks before moving on is common practice and clinically sensible. You can read about how the 0.5mg phase feels in practice on the 0.5mg Wegovy page and explore what appetite changes and side effects typically look like when you reach the 1mg stage, including typical side effects and early appetite changes, with more detail on what that step involves available on the Wegovy 1mg weight loss page.

The meaningful weight-loss data comes from the 2.4mg maintenance dose, and our guide to the 2.4mg Wegovy phase covers what that milestone looks like in practice. In the STEP 1 trial (68 weeks, adults with obesity, no diabetes) participants on 2.4mg semaglutide achieved an average body-weight reduction of around 15%, compared with about 2.4% on placebo. Those figures, published in the New England Journal of Medicine, are the numbers most often quoted when Wegovy's effectiveness is discussed. They don't describe what happens at 2.5mg, they describe where the titration leads. It's also worth noting that Novo Nordisk and the MHRA have since approved a 7.2mg maintenance dose, further extending what's possible, though the journey to it still starts at exactly this point.

Side effects at 2.5mg: what's typical and what warrants a call

The gastrointestinal side-effect profile of semaglutide (nausea, loose stools, constipation, reflux, occasional vomiting) tends to be mildest during the starter phase and most pronounced at each subsequent dose increase. That's not universal; some people feel noticeably nauseous from week one, while others barely notice anything. Both responses are within the normal range. Eating smaller portions, avoiding very fatty meals, and staying well hydrated all help. The NHS semaglutide medicines page has a full list of known side effects and flags which ones need prompt attention.

One signal that should never be waited out: severe, persistent stomach pain that radiates to the back (with or without vomiting) needs same-day medical assessment, as it can indicate acute pancreatitis. This is a recognised but infrequent risk with GLP-1 medicines, and the MHRA highlighted it in a 2026 Drug Safety Update. Injection-site redness or swelling that spreads, signs of an allergic reaction, or any symptom that feels serious enough to ask about: call 111 or contact our support team directly. Aftercare at nume runs seven days a week for exactly these moments.

Private access versus NHS: what the 2.5mg starter means practically

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), and waiting times can stretch considerably. Private treatment through a regulated online pharmacy offers a faster route, subject to clinical suitability, and it follows the same licensed dosing schedule. The cost of Wegovy privately reflects this full clinical package: consultation, prescriber review before every supply, and the medicine itself. There are no shortcuts to the 2.4mg dose, even privately, the titration exists to protect you, not to slow the service down.

If you're considering Wegovy or you've transferred from another provider and want a clinical re-review before your next pen, the process at nume starts with a free consultation reviewed the same day by a GPhC-registered Independent Prescriber. Our pharmacy is registered with the GPhC (premises number 9012878, verifiable at the GPhC register) and supplies through the licensed UK supply chain. Once approved, your treatment ships the same day and arrives the next working day with DPD. The weight-loss treatment overview covers both Wegovy and the other licensed options available through us, if you're still weighing up which might suit you. When you're ready to take that step, speak to our prescribers through a free consultation.